Literature DB >> 12740358

Mutant K-ras2 in serum.

H J N Andreyev, R Benamouzig, M Beranek, P Clarke, D Cunningham, A R Norman, W Giaretti, A F P M de Goeij, B J Iacopetta, E Jullian, K Krtolica, J Q Lee, S T Wang, N Lees, F Al-Mulla, O Muller, M Pauly, V Pricolo, A Russo, C Troungos, N Urosevic, R Ward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12740358      PMCID： PMC1773684          DOI： 10.1136/gut.52.6.915-a

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  6 in total

1.  Markers, markers everywhere..... Prognosis in colorectal cancer--time for a new approach.

Authors:  J Andreyev; D Cunningham
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

2.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

Authors:  H J Andreyev; A R Norman; D Cunningham; J R Oates; P A Clarke
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

3.  Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.

Authors:  F Al-Mulla; E J Milner-White; J J Going; G D Birnie
Journal:  J Pathol       Date:  1999-03       Impact factor: 7.996

4.  Micrometastases in esophagogastric cancer: high detection rate in resected rib segments.

Authors:  G C O'sullivan; D Sheehan; A Clarke; R Stuart; J Kelly; M D Kiely; T Walsh; J K Collins; F Shanahan
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

5.  Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation.

Authors:  W Giaretti; A Rapallo; E Geido; A Sciutto; F Merlo; M Risio; F P Rossini
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

6.  Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.

Authors:  H J Andreyev; A R Norman; D Cunningham; J Oates; B R Dix; B J Iacopetta; J Young; T Walsh; R Ward; N Hawkins; M Beranek; P Jandik; R Benamouzig; E Jullian; P Laurent-Puig; S Olschwang; O Muller; I Hoffmann; H M Rabes; C Zietz; C Troungos; C Valavanis; S T Yuen; J W Ho; C T Croke; D P O'Donoghue; W Giaretti; A Rapallo; A Russo; V Bazan; M Tanaka; K Omura; T Azuma; T Ohkusa; T Fujimori; Y Ono; M Pauly; C Faber; R Glaesener; A F de Goeij; J W Arends; S N Andersen; T Lövig; J Breivik; G Gaudernack; O P Clausen; P D De Angelis; G I Meling; T O Rognum; R Smith; H S Goh; A Font; R Rosell; X F Sun; H Zhang; J Benhattar; L Losi; J Q Lee; S T Wang; P A Clarke; S Bell; P Quirke; V J Bubb; J Piris; N R Cruickshank; D Morton; J C Fox; F Al-Mulla; N Lees; C N Hall; D Snary; K Wilkinson; D Dillon; J Costa; V E Pricolo; S D Finkelstein; J S Thebo; A J Senagore; S A Halter; S Wadler; S Malik; K Krtolica; N Urosevic
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.